In this study, we uncovered that ACER2 was a potential molecular biomarker to reflect the TME status in diverse cancers especially in BLCA, and contribute to the formation of non-inflamed TME in BLCA. This evidence concerns the gene ACER2 and bladder transitional cell carcinoma.